VivoSim Labs (NASDAQ:VIVS – Get Free Report) and MediciNova (NASDAQ:MNOV – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Profitability
This table compares VivoSim Labs and MediciNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -1,413.57% | -28.83% | -19.71% |
| MediciNova | N/A | -24.86% | -23.35% |
Earnings & Valuation
This table compares VivoSim Labs and MediciNova”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $140,000.00 | 38.78 | -$2.48 million | ($4.40) | -0.47 |
| MediciNova | $1.00 million | 69.79 | -$11.04 million | ($0.25) | -5.68 |
VivoSim Labs has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
VivoSim Labs has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for VivoSim Labs and MediciNova, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| MediciNova | 1 | 1 | 1 | 2 | 2.80 |
MediciNova has a consensus target price of $7.00, suggesting a potential upside of 392.96%. Given MediciNova’s stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than VivoSim Labs.
Insider and Institutional Ownership
8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by company insiders. Comparatively, 13.6% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
MediciNova beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
